According to our new research study on "Global Lung Cancer Screening Market Size and Forecast to 2030 - COVID-19 Impact and Global Analysis - by Cancer Type, Technology, Age Group, and End User," the market is expected to grow from US$ 2,326.5 million in 2022 to US$ 4,363.95 million by 2030; it is estimated to record a CAGR 8.2% during 2022-2030. Factors like the rising incidence of lung cancer and Increasing government support are driving the lung cancer screening market growth. Lung Cancer Screening Market- Market Opportunities - Structured Lung Cancer Screening Program Several countries face challenges with lung cancer screening programs. A few examples of population-based Australian screening programs are "BreastScreen," the "National Bowel Cancer Screening Program," and the "National Cervical Screening Program." On behalf of the Ministry of Health, the RIVM Center for Population Screening (RIVM-CvB) leads and manages the National Population Screening Programme; under which all Dutch citizens are invited, at a certain point in their lives, to participate in one of the national screening programs. The State begins, sets up, and finances three cancer population screening programs. Therefore, there is a crucial requirement for a well-structured program such as a community-based program or a shared, informed decision-making program between clinicians and potential participants; accredited reporting centers; and a central data registry for quality control, monitoring, and outcome reporting. Additionally, integrated smoking cessation intervention, international data supporting cost-effectiveness, additional mortality benefits, and a high sustainability rate are a few factors that must be studied for lung cancer screening. Further, the International Association for the Study of Lung Cancer recommends implementing feasibility screening programs in the countries of Asia Pacific without participating in lung cancer screening studies. These programs involve smoking cessation initiatives, standardized algorithms for selecting and managing screening participants, and specialist multidisciplinary teams to manage participants with positive screening results. Therefore, the implementation of structured lung cancer screening programs is expected to be a lucrative opportunity in the lung cancer screening market during the forecast period. The lung cancer screening market, by cancer type, is segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer. The non-small cell lung cancer (NSCLC) segment held the largest market share in 2022. However, the small cell lung cancer is expected to grow with a CAGR of 9.0% from 2022 to 2030. Non-small cell lung cancer (NSCLC) occurs when abnormal cells proliferate in the lung tissues. There are three primary forms of NSCLC cancer